Insights

Specialty drugs can produce miraculous outcomes for patients, providers, and health benefits leaders alike. Specialty drugs are a challenge, a source of frustration for patients, providers, and health benefits leaders alike. That’s the interesting thing about specialty drugs. The relatively new class of therapies has, in many cases, kept workers alive and productive in the face of…

John didn’t know it, but his health was sliding dangerously close to the edge of a cliff. Once over the edge, there would be no going back. It was a point of no return, and a life of permanent sickness, high expense and dependency. Fortunately for John (which, for privacy protection, is not his real name),…

The conclusions of health benefits analysts are consistent: After a dip in 2020, health benefit costs are rising again, and trends are returning to pre-pandemic levels. That’s not the whole story, however. Something else has grown to such importance that, for many employers, it has become the imperative in defining their employee benefit plans in the post-pandemic…